AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16978630 — intervention group
Group type: COMPARATOR
Intervention: Uninfected men
Number of subjects: 263
Study 16978630 — intervention group
Group type: EXPERIMENTAL
Intervention: Infected women
Number of subjects: 263
Study 16978630 — intervention group
Group type: COMPARATOR
Intervention: Uninfected women
Number of subjects: 263
Study 10394855 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily doses of 100 mg for 3 months (fingernail) or 4 months (toenail) - Group A
Number of subjects: 153
Study 10394855 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pulse therapy with daily doses of 400 mg - Group B
Number of subjects: 153
Study 10394855 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pulse therapy with daily doses of 300 mg - Group C
Number of subjects: 153
Study 10394855 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pulse therapy with daily doses of 200 mg - Group D
Number of subjects: 153
Study 10394855 — intervention group
Group type: EXPERIMENTAL
Intervention: Further treatment with daily doses of 400 mg for non-cured patients
Number of subjects: 153
Study 8688391 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-eclampsia with intrauterine growth retardation (IUGR)
Number of subjects: 66
Study 8688391 — intervention group
Group type: COMPARATOR
Intervention: Pre-eclampsia without IUGR
Number of subjects: 66
Study 8688391 — intervention group
Group type: COMPARATOR
Intervention: Nonpre-eclamptic pregnancy
Number of subjects: 66
Study 1863726 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP) 0.3 microgram/kg over 15 minutes
Number of subjects: 15
Study 1863726 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 15
Study 1863726 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP)
Number of subjects: 15
Study 7117360 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (PN 30 + 30 mg)
Number of subjects: 12
Study 7117360 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort (DF 36 + 36 mg)
Number of subjects: 12
Study 7117360 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 12
Study 7117360 — intervention group
Group type: COMPARATOR
Intervention: Comparison between PL and PN
Number of subjects: 12
Study 7117360 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between DF and PN
Number of subjects: 12
Study 31208680 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness and acceptance-based self-help approach (book)
Number of subjects: 117
Study 31208680 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 117
Study 30232528 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB 50 mg/kg orally
Number of subjects: 16
Study 30232528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 27090032 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated Sprint Training (RST, at 90% HRpeak)
Number of subjects: 13
Study 27090032 — intervention group
Group type: COMPARATOR
Intervention: Moderate Intensity Continuous Training (MCT, at 70% HRpeak)
Number of subjects: 13
Study 27090032 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RST and MCT
Number of subjects: 13
Study 24601887 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of plain 1% 2-chloroprocaine (Group C, n = 66)
Number of subjects: 130
Study 24601887 — intervention group
Group type: COMPARATOR
Intervention: 10 mg of plain 0.5% bupivacaine (Group B, n = 64)
Number of subjects: 130
Study 20015098 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (4.0 mg)
Number of subjects: 11
Study 20015098 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 11
Study 19537284 — intervention group
Group type: EXPERIMENTAL
Intervention: C/BPO HE (clindamycin 1%-BPO 5% topical gel with hydrating excipients)
Number of subjects: 20
Study 19537284 — intervention group
Group type: COMPARATOR
Intervention: C/BPO (clindamycin 1%-BPO 5% topical gel without hydrating excipients)
Number of subjects: 20
Study 17888700 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented BMD report containing 5‐yr and lifetime absolute hip fracture risk estimates
Number of subjects: 0
Study 17888700 — intervention group
Group type: COMPARATOR
Intervention: Basic BMD report
Number of subjects: 0
Study 15249367 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision restoration/rehabilitation intervention (details not specified)
Number of subjects: 1591
Study 11552769 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 1056
Study 9882080 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol 25 mg (37 mg of the trometamol salt)
Number of subjects: 54
Study 9882080 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen 50 mg
Number of subjects: 54
Study 9882080 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen free acid 25 mg
Number of subjects: 54
Study 9882080 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexketoprofen trometamol 25 mg (repeated dose, twice daily for 7 days)
Number of subjects: 54
Study 8002761 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer format of the Sickness Impact Profile (SIP)
Number of subjects: 48
Study 8002761 — intervention group
Group type: COMPARATOR
Intervention: Paper format of the Sickness Impact Profile (SIP)
Number of subjects: 48
Study 2911205 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin (50 mg/m2, IV) on days 1‐3; cytarabine (Ara‐C) (25 mg/m2, IV) bolus, followed by 160 mg/m2 as a continuous IV infusion daily for 5 days and 6‐thioguanine (6‐TG) (100 mg/m2 po) every 12 hr daily for 5 days (DAT)
Number of subjects: 96
Study 2911205 — intervention group
Group type: EXPERIMENTAL
Intervention: Amsacrine (190 mg/m2, IV) on days 1‐3 with Ara‐C and 6‐TG at the above doses (AAT)
Number of subjects: 96
Study 2911205 — intervention group
Group type: COMPARATOR
Intervention: Maintenance therapy (alternating cycles of vincristine/methotrexate, cyclophosphamide/6‐TG, daunorubicin/hydroxyurea and Ara‐C/6‐TG)
Number of subjects: 96
Study 2911205 — intervention group
Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 96
Study 30650341 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar coagulation
Number of subjects: 199
Study 30650341 — intervention group
Group type: COMPARATOR
Intervention: Monopolar cut
Number of subjects: 199
Study 28821468 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care behavioral intervention
Number of subjects: 0
Study 28821468 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 26493430 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care
Number of subjects: 150
Study 26493430 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 150
Study 26493430 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study 23993727 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 11
Study 23993727 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 11
Study 23993727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 21270183 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Testing Group (STG) with enhanced usual care and structured self-monitoring of blood glucose (SMBG)
Number of subjects: 483
Study 21270183 — intervention group
Group type: COMPARATOR
Intervention: Active Control Group (ACG) with enhanced usual care
Number of subjects: 483
Study 21270183 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Testing Group (STG)
Number of subjects: 483
Study 21270183 — intervention group
Group type: COMPARATOR
Intervention: Active Control Group (ACG)
Number of subjects: 483
Study 21270183 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (STG and ACG)
Number of subjects: 483
Study 19882578 — intervention group
Group type: COMPARATOR
Intervention: Conventional phacoemulsification (group 1)
Number of subjects: 100
Study 19882578 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsional phacoemulsification (OZil, group 2)
Number of subjects: 100
Study 16798668 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell saver group
Number of subjects: 60
Study 16798668 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 12558839 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 0
Study 12558839 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 0
Study 10792161 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant cisplatin
Number of subjects: 51
Study 10792161 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 51
Study 9348577 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/5-FU (group 1): Cisplatin 100 mg/m2 on day 1 followed by continuous infusion of 5-FU 1,000 mg/m2/day on days 2-6, repeated every 21 days for four cycles.
Number of subjects: 67
Study 9348577 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin/UFT (group 2): Cisplatin 100 mg/m2 on day 1 followed by oral UFT 300 mg/m2/day on days 2-20, repeated every 21 days for four cycles.
Number of subjects: 67
Study 8396102 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 10 mg/kg (maximum 500 mg) for three days
Number of subjects: 96
Study 8396102 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V at a dose of 125 mg or 250 mg qid for ten days
Number of subjects: 96
Study 3701861 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical conditioning therapy (54 10‐min immersions of both hands in water at 43 degrees C, with whole‐body exposure to cold air at 0 degrees C, three times per day, 3 days per week, for 6 weeks)
Number of subjects: 0
Study 3701861 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback therapy (eight sessions of electromyograph feedback while listening to relaxation tapes, followed by 10 sessions of digital thermal feedback while listening to relaxation tapes)
Number of subjects: 0
Study 29066464 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab (162 mg weekly)
Number of subjects: 87
Study 29066464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 27602924 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation (50 Gy per 25 fractions) and 5‐fluorouracil infusion (arm A)
Number of subjects: 318
Study 27602924 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation (50 Gy per 25 fractions) and 5‐fluorouracil infusion combined with oxaliplatin (arm B)
Number of subjects: 318
Study 27602924 — intervention group
Group type: COMPARATOR
Intervention: Preoperative chemotherapy with 5‐fluorouracil and oxaliplatin without radiation (arm C)
Number of subjects: 318
Study 23733529 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0
Study 23584671 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 20
Study 23584671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 20811556 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate (higher than 300 mg/d)
Number of subjects: 0
Study 20811556 — intervention group
Group type: COMPARATOR
Intervention: Pentosan polysulfate (300 mg/d)
Number of subjects: 0
Study 20811556 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate (duration of therapy)
Number of subjects: 0
Study 20811556 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful therapy
Number of subjects: 0
Study 20811556 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom improvement with therapy
Number of subjects: 0
Study 20811556 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium Sensitivity Test
Number of subjects: 0
Study 20811556 — intervention group
Group type: EXPERIMENTAL
Intervention: O'Leary-Sant Interstitial Cystitis Symptom Index
Number of subjects: 0
Study 18171211 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term daily aspirin use
Number of subjects: 139
Study 18171211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 16155280 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (E+P) therapy, n = 437
Number of subjects: 835
Study 16155280 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n = 398
Number of subjects: 835
Study 12855528 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual outreach (joint teleconsultation)
Number of subjects: 3170
Study 12855528 — intervention group
Group type: COMPARATOR
Intervention: Standard outpatient appointments
Number of subjects: 3170
Study 10539778 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: iron + folate (60 mg and 250 microg, respectively) daily for 3 mo, then folate (250 microg) weekly for 4 mo
Number of subjects: 116
Study 10539778 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: folate daily, and 60 mg iron only once weekly for 3 mo, then weekly iron + folate for 4 mo
Number of subjects: 116
Study 10539778 — intervention group
Group type: COMPARATOR
Intervention: Group 3: folate daily for 3 mo and then weekly for 4 mo
Number of subjects: 116
Study 10539778 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation over 7 mo (30 doses)
Number of subjects: 116
Study 8690193 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lactulose (20 g)
Number of subjects: 13
Study 8690193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracolonic lactose (20 g)
Number of subjects: 13
Study 8690193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracolonic SCFAs (54 mmol/180 mL and 90 mmol/180 mL)
Number of subjects: 13
Study 8690193 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 13
Study 8690193 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma oxyntomodulin‐like immunoreactivity and glucagon‐like peptide 1
Number of subjects: 13
Study 8690193 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide YY
Number of subjects: 13
Study 1879271 — intervention group
Group type: EXPERIMENTAL
Intervention: modified Ayre spatula plus Zelsmyr Cytobrush (90 cases)
Number of subjects: 192
Study 1879271 — intervention group
Group type: COMPARATOR
Intervention: modified Ayre spatula plus bulb aspirator (102 cases)
Number of subjects: 192
Study 7049781 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral soluble human (semi-synthetic) insulin
Number of subjects: 6
Study 7049781 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine insulin
Number of subjects: 6
Study 28635364 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 234
Study 28635364 — intervention group
Group type: COMPARATOR
Intervention: Lecture
Number of subjects: 234
Study 28635364 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 234
Study 26946343 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) every 8 weeks for 200 weeks
Number of subjects: 297
Study 26946343 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 8 weeks for 200 weeks
Number of subjects: 297
Study 24513806 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin plus sublingual nitrate (group A)
Number of subjects: 300
Study 24513806 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin plus sublingual placebo (group B)
Number of subjects: 300
Study 23154692 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at rehabilitation residence for pregnant women with substance-use disorders
Number of subjects: 96
Study 23154692 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at prenatal clinic for women with substance-use disorders
Number of subjects: 96
Study 23154692 — intervention group
Group type: COMPARATOR
Intervention: Control group (no attendance at rehabilitation residence)
Number of subjects: 96
Study 20224057 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive capsulitis (AC)
Number of subjects: 10935
Study 20224057 — intervention group
Group type: COMPARATOR
Intervention: Control group (randomly selected, 32,805 patients)
Number of subjects: 10935
Study 18440400 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructed social support from their partner
Number of subjects: 63
Study 18440400 — intervention group
Group type: COMPARATOR
Intervention: No social support
Number of subjects: 63
Study 18440400 — intervention group
Group type: EXPERIMENTAL
Intervention: Secure attachment
Number of subjects: 63
Study 18440400 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of social support and secure attachment
Number of subjects: 63
Study 16158207 — intervention group
Group type: EXPERIMENTAL
Intervention: Detralex 500 mg (2 tablets 3 times daily for 5 days after the operation)
Number of subjects: 63
Study 16158207 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Detralex treatment)
Number of subjects: 63
Study 12568734 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg OD of natural conjugated estrogens during 4 months
Number of subjects: 30
Study 12568734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10800013 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive, school-based self-esteem education program
Number of subjects: 470
Study 10800013 — intervention group
Group type: COMPARATOR
Intervention: Control group (scheduled personal development and health class)
Number of subjects: 470
Study 8972794 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral microwave thermotherapy (TUMT)
Number of subjects: 115
Study 8972794 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 115
Study 1454434 — intervention group
Group type: EXPERIMENTAL
Intervention: APDT (Acellular Pertussis Vaccine with Lederle Diphtheria and Tetanus Toxoids)
Number of subjects: 0
Study 1454434 — intervention group
Group type: COMPARATOR
Intervention: APDT-T/J (Commercially available Japanese Takeda vaccine)
Number of subjects: 0
Study 3931661 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol 1 mg kg‐1
Number of subjects: 30
Study 3931661 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 0.5 mg kg‐1
Number of subjects: 30
Study 3931661 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 1 mg kg‐1
Number of subjects: 30
Study 30737551 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 adjuvant monotherapy
Number of subjects: 355
Study 30041885 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed group
Number of subjects: 100
Study 30041885 — intervention group
Group type: EXPERIMENTAL
Intervention: Powdered formula group
Number of subjects: 100
Study 30041885 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feeding)
Number of subjects: 100
Study 30041885 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottle-fed mother's milk group
Number of subjects: 100
Study 26826629 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary lifestyle intervention
Number of subjects: 54
Study 26826629 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 54
Study 24942703 — intervention group
Group type: EXPERIMENTAL
Intervention: strength training + a-tDCS
Number of subjects: 10
Study 24942703 — intervention group
Group type: EXPERIMENTAL
Intervention: a-tDCS alone
Number of subjects: 10
Study 24942703 — intervention group
Group type: COMPARATOR
Intervention: strength training + sham-tDCS
Number of subjects: 10
Study 24942703 — intervention group
Group type: COMPARATOR
Intervention: tDCS alone
Number of subjects: 10
Study 22054659 — intervention group
Group type: EXPERIMENTAL
Intervention: ONCAB
Number of subjects: 2103
Study 22054659 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB
Number of subjects: 2103
Study 22054659 — intervention group
Group type: EXPERIMENTAL
Intervention: POAF
Number of subjects: 2103
Study 21055664 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitization with cow's milk (CM)
Number of subjects: 30
Study 21055664 — intervention group
Group type: COMPARATOR
Intervention: Soy milk (control)
Number of subjects: 30
Study 17693380 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 3029
Study 17693380 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol tartrate
Number of subjects: 3029
Study 15818609 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health Treatment Court (MHTC)
Number of subjects: 235
Study 15818609 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 235
Study 10851775 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot massage (10 minutes, 5 minutes per foot)
Number of subjects: 87
Study 9291724 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioral Therapy for Sexually Abused Preschoolers (CBT‐SAP)
Number of subjects: 43
Study 9291724 — intervention group
Group type: COMPARATOR
Intervention: Nondirective supportive therapy (NST)
Number of subjects: 43
Study 8241988 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. immunoglobulin (1.0 g/kg once weekly for 120 days after transplant) plus CMV‐seronegative blood products
Number of subjects: 51
Study 8241988 — intervention group
Group type: COMPARATOR
Intervention: CMV‐seronegative blood products alone
Number of subjects: 51
Study 3516097 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide (cholecystokinin decapeptide)
Number of subjects: 20
Study 3516097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3516097 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting bile acid levels
Number of subjects: 20
Study 3516097 — intervention group
Group type: EXPERIMENTAL
Intervention: Alanine aminotransferase
Number of subjects: 20
Study 29488798 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling on a heart-healthy diet and physical activity (PA) plus access to a smartphone app for 3 months.
Number of subjects: 833
Study 29488798 — intervention group
Group type: COMPARATOR
Intervention: Counselling on a heart-healthy diet and physical activity (PA) only (Control Group).
Number of subjects: 833
Study 25834945 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia consent process
Number of subjects: 200
Study 25834945 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced interactivity
Number of subjects: 200
Study 25834945 — intervention group
Group type: COMPARATOR
Intervention: Multimedia condition
Number of subjects: 200
Study 23746872 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 81
Study 23746872 — intervention group
Group type: COMPARATOR
Intervention: Control (no prednisolone)
Number of subjects: 81